Filtered By:
Condition: Stroke
Drug: Actos

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 156 results found since Jan 2013.

Ten‐year observational follow‐up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
ConclusionsThe trends of macrovascular benefits of pioglitazone compared with placebo during PROactive did not persist in the absence of continued pioglitazone during this 10‐year follow‐up. Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow‐up; however, these imbalances should be interpreted with caution because of the limitations of the observational study design.
Source: Diabetes, Obesity and Metabolism - January 8, 2016 Category: Endocrinology Authors: E. Erdmann, S. Harding, H. Lam, A. Perez Tags: ORIGINAL ARTICLE Source Type: research

10‐Year Observational Follow‐Up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
ConclusionsThe trends of macrovascular benefits of pioglitazone compared with placebo during PROactive did not persist in the absence of continued pioglitazone during this 10‐year follow‐up. Trends of decreased bladder cancer and increased prostate cancer were observed in the pioglitazone group during follow‐up; however, these imbalances should be interpreted with caution due to limitations of the observational study design.
Source: Diabetes, Obesity and Metabolism - November 23, 2015 Category: Endocrinology Authors: Erland Erdmann, Sarah Harding, Hung Lam, Alfonso Perez Tags: ORIGINAL ARTICLE Source Type: research

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
CONCLUSIONS: PPAR-γ agonists appear to reduce recurrent stroke and total events of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, and improve insulin sensitivity and the stabilisation of carotid plaques. There is evidence of limited quality that they are well tolerated. However, the conclusions should be interpreted with caution considering the small number and the quality of the included studies. In future, well-designed, double-blind RCTs with large samples are required to assess the efficacy and safety of PPAR-γ agonists in the secondary prevention of stroke and related vascular events in p...
Source: Cochrane Database of Systematic Reviews - October 29, 2015 Category: Journals (General) Authors: Liu J, Wang LN Tags: Cochrane Database Syst Rev Source Type: research

Hyperglycemia and PPAR{gamma} Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke Basic Sciences
Conclusions— Hyperglycemia and macrophage-specific PPAR activation exert opposing effects on MO/MP polarization in ischemic stroke lesions and, thereby, critically determine the risk of hemorrhagic infarct transformation.
Source: Stroke - September 28, 2015 Category: Neurology Authors: Gliem, M., Klotz, L., van Rooijen, N., Hartung, H.-P., Jander, S. Tags: Animal models of human disease, Coumarins, Other diabetes, Acute Cerebral Hemorrhage, Acute Cerebral Infarction, Anticoagulants Basic Sciences Source Type: research

Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers.
CONCLUSIONS: Pioglitazone is endowed with neuroprotective properties which are probably mediated by its antioxidant, anti-inflammatory, and anti-apoptotic mechanisms hence may provide a successful agent for the management of ischemic stroke. PMID: 26398383 [PubMed - in process]
Source: Pharmacological Reports - September 26, 2015 Category: Drugs & Pharmacology Authors: El-Sahar AE, Safar MM, Zaki HF, Attia AS, Ain-Shoka AA Tags: Pharmacol Rep Source Type: research

Number needed to harm in the post‐marketing safety evaluation: results for rosiglitazone and pioglitazone
ConclusionThe NNH values suggested an increased CV risk with rosiglitazone versus pioglitazone across several sources of information. The inclusion of objective metrics in post‐marketing drug's benefit–risk assessments could be of increased value and help RAs to make consistent decisions on drug safety. Copyright © 2015 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - September 1, 2015 Category: Drugs & Pharmacology Authors: Diogo Mendes, Carlos Alves, Francisco Batel‐Marques Tags: Original Report Source Type: research

Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study.
CONCLUSIONS: While this study was too underpowered to determine the effect of pioglitazone, the result failed to show beneficial effects in patients of ischemic stroke or TIA with impaired glucose tolerance and newly diagnosed diabetes. PMID: 26269002 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - August 15, 2015 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which patients wer...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Publication date: Available online 23 June 2015 Source:The Lancet Neurology Background A systematic assessment of potential disease-modifying compounds for Parkinson's disease concluded that pioglitazone could hold promise for the treatment of patients with this disease. We assessed the effect of pioglitazone on the progression of Parkinson's disease in a multicentre, double-blind, placebo-controlled, futility clinical trial. Methods Participants with the diagnosis of early Parkinson's disease on a stable regimen of 1 mg/day rasagiline or 10 mg/day selegiline were randomly assigned (1:1:1) to 15 mg/day pioglitazone, 45 mg...
Source: The Lancet Neurology - June 24, 2015 Category: Neurology Source Type: research

Protective Role of Peroxisome Proliferator-Activated Receptor-{gamma} in the Development of Intracranial Aneurysm Rupture Basic Sciences
Conclusions— Our data showed that the activation of macrophage PPAR protects against the development of aneurysmal rupture. PPAR in inflammatory cells may be a potential therapeutic target for the prevention of aneurysmal rupture.
Source: Stroke - May 22, 2015 Category: Neurology Authors: Shimada, K., Furukawa, H., Wada, K., Korai, M., Wei, Y., Tada, Y., Kuwabara, A., Shikata, F., Kitazato, K. T., Nagahiro, S., Lawton, M. T., Hashimoto, T. Tags: Animal models of human disease, Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage, Aneurysm, AVM, hematoma Basic Sciences Source Type: research

Cardiovascular risks associated with second‐line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study
ConclusionThere were no differences in overall cardiovascular risks among several add‐on second‐line oral antidiabetic agents; however, glinide plus metformin and α‐glucosidase inhibitors plus metformin combination therapies might be associated with lower risks of acute myocardial infarction.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - May 1, 2015 Category: Endocrinology Authors: Y.‐C. Chang, L.‐M. Chuang, J.‐W. Lin, S.‐T. Chen, M.‐S. Lai, C.‐H. Chang Tags: Research Article Source Type: research

Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity.
Authors: Ferrari SM, Fallahi P, Vita R, Antonelli A, Benvenga S Abstract Peroxisome proliferator-activated receptor- (PPAR-) γ expression has been shown in thyroid tissue from patients with thyroiditis or Graves' disease and furthermore in the orbital tissue of patients with Graves' ophthalmopathy (GO), such as in extraocular muscle cells. An increasing body of evidence shows the importance of the (C-X-C motif) receptor 3 (CXCR3) and cognate chemokines (C-X-C motif) ligand (CXCL)9, CXCL10, and CXCL11, in the T helper 1 immune response and in inflammatory diseases such as thyroid autoimmune disorders. PPAR-γ agoni...
Source: PPAR Research - February 28, 2015 Category: Genetics & Stem Cells Tags: PPAR Res Source Type: research

Peroxisome Proliferator-activated Receptor-γ Agonist Pioglitazone Ameliorates White Matter Lesion and Cognitive Impairment in Hypertensive Rats.
CONCLUSIONS: Long-term treatment of pioglitazone has beneficial effect on hypertension-induced WML and cognition decline, which may partly through its effect on attenuation of arteriolar remodeling, endothelial activation, and brain inflammation. PMID: 25611692 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - January 22, 2015 Category: Neuroscience Authors: Lan LF, Zheng L, Yang X, Ji XT, Fan YH, Zeng JS Tags: CNS Neurosci Ther Source Type: research

Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial
Publication date: December 2014 Source:American Heart Journal, Volume 168, Issue 6 Author(s): Catherine M. Viscoli , Lawrence M. Brass , Antonio Carolei , Robin Conwit , Gary A. Ford , Karen L. Furie , Mark Gorman , Peter D. Guarino , Silvio E. Inzucchi , Anne M. Lovejoy , Mark W. Parsons , Peter N. Peduzzi , Peter A. Ringleb , Gregory G. Schwartz , J. David Spence , David Tanne , Lawrence H. Young , Walter N. Kernan Background Recurrent vascular events remain a major source of morbidity and mortality after stroke or transient ischemic attack (TIA). The IRIS Trial is evaluating an approach to secondary prevention based o...
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research

Risk factors associated with abnormal cognition in Japanese outpatients with diabetes, hypertension or dyslipidemia
Conclusions Because of the higher prevalence of abnormal cognition in aged outpatients with diabetes found in primary care practice and significant associations with serum albumin, uric acid, renal function, retinopathy and antidiabetic drugs, there is a need for early diagnosis and strategies against dementia.
Source: Diabetology International - November 9, 2014 Category: Endocrinology Source Type: research